Key Points
- To evaluate the clinical efficacy, dosing, and safety profile of amiodarone in patients presenting with life-threatening or treatment-refractory cardiac arrhythmias.
- Administered amiodarone to 40 patients with refractory tachyarrhythmias (18 with recurrent ventricular tachycardia and 22 with supraventricular arrhythmias) over an average follow-up of 10 months.
- Maintained patients on a mean daily dose of 300 mg for ventricular tachyarrhythmias and 200 mg for supraventricular tachyarrhythmias.
- Achieved excellent or good arrhythmia control in 94.4% (17/18) of patients with ventricular tachycardia and 90.9% (20/22) of patients with supraventricular arrhythmias.
- Observed frequent adverse reactions including corneal microdeposits, skin discoloration, thyroid dysfunction, and symptomatic bradycardia, with only 5.0% (2/40) requiring treatment discontinuation.
- Precipitation or exacerbation of heart failure did not occur in any patient, despite the presence of severe left ventricular dysfunction in many participants.
Structured PICO
Does amiodarone improve arrhythmia control in patients with life-threatening or refractory tachyarrhythmias?
PPopulation40 patients with life-threatening or refractory tachyarrhythmias (18 with recurrent ventricular tachycardia, 22 with supraventricular arrhythmias)
IInterventionAmiodarone (mean daily maintenance dose 300 mg for ventricular tachyarrhythmias and 200 mg for supraventricular tachyarrhythmias)
OOutcomeArrhythmia control (assessed as excellent or good)
Amiodarone is highly effective for controlling life-threatening or refractory ventricular and supraventricular tachyarrhythmias, with common but generally manageable side effects.